Vietnam Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

Vietnam Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Vietnam Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $6 Mn in 2022 and is projected to reach US $9 Mn in 2030, exhibiting a CAGR of 6.03% during the forecast period.

Mutations in the PKD1 and PKD2 genes produce autosomal dominant polycystic kidney disease (ADPKD), a hereditary disorder affecting several organs. This causes the kidneys to enlarge(renomegaly) as fluid-filled cysts begin to form in them. The majority of ADPKD cases result in renal failure (ESKD). Fatigue, discomfort, and recurrent infections are typical symptoms. This rare condition has no known cure, although symptoms can be managed and complications can be avoided with treatment. The only medication approved for ADPKD is tolvaptan (Jinarc), made by Otsuka Pharmaceuticals, which is effective in certain patients by acting as a vasopressin blocker to decrease the formation of cysts. Pain management and lifestyle changes are additional therapy possibilities. A number of treatments have been developed to treat ADPKD, such as mTOR inhibitors (Everolimus, Sirolimus), however, they have not been successful in preventing the disease progression.

The evidence suggests the overall prevalence of ADPKD is around 1 in 400 to 1 in 1000 individuals in Vietnam. It is anticipated that the number of ADPKD patients will rise due to factors including longer life expectancies and an aging population, as well as modifiable risk factors like dietary changes, lifestyle adjustments, and physical inactivity. The market is therefore driven by major factors like rising prevalence, a shifting healthcare landscape, improved access, and evolving treatment options in the industry. However, conditions such as high costs of treatment, a lack of specialists like nephrologists, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in the prevalence of ADPKD: According to several estimates, the expected prevalence of ADPKD is around 1 in 400 to 1 in 1000 individuals in Vietnam. Factors such as increased life span and geriatric population, along with modifiable risk factors like diet, lifestyle changes, and physical inactivity, are expected to increase the patient pool of ADPKD patients requiring advanced treatments, resulting in the growth of the market.

Shifting healthcare landscape: Vietnam's healthcare system is evolving, providing improved access to specialized care and diagnostic resources, potentially energizing the ADPKD therapeutics market. As the economy grows, healthcare spending in Vietnam is expected to increase, enhancing the accessibility of ADPKD treatments and broadening their market presence.

Evolving treatment options: The development of novel therapies aimed at reducing ADPKD progression and combined treatments targeting different aspects of the condition could establish untapped market segments. Increased awareness among healthcare providers and patients regarding ADPKD and the available treatments drives market growth.

Increased awareness: Increasing public awareness and educational campaigns promote early diagnosis, enabling timely interventions and potentially widening the market for treatments focused on slowing the advancement of the disease. Groups such as the Vietnam Kidney Foundation and the Vietnam Association of Rare Diseases work towards improving patient access and care, influencing evidence-based policy decisions by gathering data that propels the therapeutics market.

Market Restraints

High costs of treatment: Innovative treatments for ADPKD, notably gene therapy approaches, may incur significant costs. Despite insurance coverage by the government, patients might encounter financial challenges. Currently, there's a limited implementation of tiered pricing systems that offer subsidized rates for essential medications, specifically ADPKD drugs, in Vietnam. This situation could restrict treatment access and hinder market advancement.

Lack of specialists: In rural areas of Vietnam, patients with ADPKD face restricted access to specialized care and suitable treatment options due to the concentration of nephrologists and other experts in major cities. The disproportionate number of patients compared to available specialists can curtail consultation time and the quality of care provided to individuals with ADPKD.

Socioeconomic conditions: Financial hardship, absence of social support, and restricted educational opportunities adversely affect the capacity of ADPKD patients to handle their condition and result in non-compliance with treatment regimens that hamper market growth.

Healthcare Policies and Regulatory Landscape

Vietnam's healthcare policy and regulatory system encompass multiple crucial entities and bodies. The principal authority overseeing healthcare regulations and licensing in Vietnam is the Drug Administration of Vietnam, operating under the Ministry of Health (MOH). The MOH bears the responsibility of formulating national health policies, orchestrating healthcare reforms, and supervising healthcare services.

Acquiring a license for healthcare products in Vietnam necessitates compliance with the MOH's regulations. Companies dealing with pharmaceuticals and medical devices must obtain registration and marketing approval from the MOH. This process involves presenting technical and scientific data to validate the safety, quality, and effectiveness of the product.

Vietnam's healthcare policy and regulatory framework involve various agencies and bodies, with the MOH playing a central role in regulating healthcare products. Both the public and private healthcare sectors in the country present diverse opportunities for companies engaged in the healthcare industry.

Competitive Landscape

Key Players

• Otsuka Pharmaceutical Co., Ltd
• Regulus Therapeutics
• Palladio Biosciences
• Reata Pharmaceuticals
• Galapagos NV
• Exelixis Inc
• AceLink Therapeutics, Inc
• Sanofi
• Xortx Therapeutics
• Pano Therapeutics